EcoDrugPlus

Pim-2 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSMPUG00000013731
Gene Symbol: PIM2
2 Cross references
115 Possible Orthologues:

Rar Related Orphan Receptor C

Ensembl ID : ENSMPUG00000003550
Gene Symbol: RORC
2 Cross references
382 Possible Orthologues:

Rela Proto-Oncogene, Nf-Kb Subunit

Ensembl ID : ENSMPUG00000011637
Gene Symbol: RELA
2 Cross references
199 Possible Orthologues:

Ros Proto-Oncogene 1, Receptor Tyrosine Kinase

Ensembl ID : ENSMPUG00000014298
Gene Symbol: ROS1
2 Cross references
124 Possible Orthologues:

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSMPUG00000017185
Gene Symbol: RAF1
2 Cross references
215 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSMPUG00000005488
Gene Symbol: ROCK1
2 Cross references
215 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSMPUG00000013549
Gene Symbol: ROCK2
2 Cross references
304 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSMPUG00000017762
Gene Symbol: SRC
4 Cross references
262 Possible Orthologues:

Tek Receptor Tyrosine Kinase

Ensembl ID : ENSMPUG00000015934
Gene Symbol: TEK
2 Cross references
164 Possible Orthologues:

Ttk Protein Kinase

Ensembl ID : ENSMPUG00000018096
Gene Symbol: TTK
2 Cross references
203 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSMPUG00000007689
Gene Symbol: UGCG
2 Cross references
211 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSMPUG00000012805
Gene Symbol: WEE1
2 Cross references
226 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).